pp-259 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Heart injury, Heart arrhythmia, Ischemic heart disease
Clinical stage: Phase 2
Modality: Small molecule
Mechanism & Target: Not disclosed
Route & form: Oral
Differentiation: Not disclosed
Manufacturer #39673
A clinical-stage biopharmaceutical company focused on cardiovascular. Developing a small molecule therapeutic targeting cardiovascular with global development focus. Pipeline positioned for regulatory advancement in key markets.
None